Ziemssen, T.; Groth, M.; Winkelmann, V.E.; Bopp, T.
Correction: Ziemssen et al. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). Vaccines 2023, 11, 1374. Vaccines 2024, 12, 911.
https://doi.org/10.3390/vaccines12080911
AMA Style
Ziemssen T, Groth M, Winkelmann VE, Bopp T.
Correction: Ziemssen et al. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). Vaccines 2023, 11, 1374. Vaccines. 2024; 12(8):911.
https://doi.org/10.3390/vaccines12080911
Chicago/Turabian Style
Ziemssen, Tjalf, Marie Groth, Veronika Eva Winkelmann, and Tobias Bopp.
2024. "Correction: Ziemssen et al. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). Vaccines 2023, 11, 1374" Vaccines 12, no. 8: 911.
https://doi.org/10.3390/vaccines12080911
APA Style
Ziemssen, T., Groth, M., Winkelmann, V. E., & Bopp, T.
(2024). Correction: Ziemssen et al. Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC). Vaccines 2023, 11, 1374. Vaccines, 12(8), 911.
https://doi.org/10.3390/vaccines12080911